PER-072-00已完成未知
COMPARATIVE RANDOMIZED DOUBLE BLIND MULTICENTRIC STUDY WHICH EVALUATES THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF MK-0826 VERSUS CEFEPIME IN THE TREATMENT OF HOSPITAL ACQUIRED PNEUMONIA IN ADULTS
MERCK SHARP & DOHME PERU S.R.L.,0 个研究点目标入组 0 人开始时间: 2000年1月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- 未提供
排除标准
- •Patients under 18 years of age.
- •Patients who have received an effective antibiotic treatment for pneumonia for more than one day (24 hours).
- •Patients who have previously had serious allergies or other serious reactions to certain antibiotics, including Carbapenem, Cefepime or other penicillins or Cephalosporins or Metronidazole.
- •Patients who have a rapidly evolving disease or terminal illness.
- •Patients whose kidney or liver is working very poorly, determined by a blood test or those who require dialysis.
- •Patients who have AIDS or those who are taking medications that serve to lower the defenses (immunosuppressants).
- •Patients who are participating or have participated in another medical study that involves the use of a research drug, within the last 30 days or if you have participated in this study before.
- •Patients with lung cancer or cancer that has spread to the lung or cystic fibrosis.
研究者
相似试验
进行中（未招募）
不适用
MULTICENTRIC COMPARATIVE RANDOMIZED DOUBLE BLIND CROSS OVER STUDY WITH TACROLIMUS (FK506)0.1% EYEDROPS AND CYCLOSPORINE 1% EYEDROPS IN CHILDREN WITH SEVERE ACTIVE VERNAL KERATOCONJUNCTIVITIS, LASTING 7 WEEKS, FOLLOWED BY AN OPEN TRIAL LASTING 24 MONTHS TO EVALUATE LONG TERM EFFICACY AND SAFETY OF THE TREATMENT - NDVernal KeratoconjunctivitisMedDRA version: 9.1Level: SOCClassification code 10015919Term: Eye disordersEUCTR2008-001502-17-ITAZIENDA OSPEDALIERA MEYER
已完成
不适用
RANDOMIZED, DOUBLE-BLIND, MULTICENTRIC COMPARATIVE STUDY, PHASE III, WITH TWO COURSES OF DIFFERENT THERAPY WITH BMS-284756 ORAL VS AMOXICILLINE / ORAL CLAVULANATE IN THE TREATMENT OF ACUTE SINUSITISPER-054-01BRISTOL MYERS SQUIBB PERU S.A.,
未知
不适用
MULTICENTRIC DOUBLE BLIND RANDOMIZED PARALLEL STUDY CONTROLLED WITH PLACEBO AND ACTIVE COMPARATOR TO EVALUATE THE EFFECTIVENESS OF THE ALTERATION OF LIPIDS, SAFETY AND TOLERABILITY OF L-410198 IN PATIENTS WITH MIXED HYPERLIPIDEMIA (CHOLESTEROL AND ELEVATED TRIGLYCERIDES)PER-030-00MERCK SHARP & DOHME PERU S.R.L.,
进行中（未招募）
不适用
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND COMPARISON OF 4 DOSEREGIMENS OF PLA-695, NAPROXEN, AND PLACEBO ADMINISTERED DAILYFOR 6 WEEKS IN SUBJECTS WITH ACTIVE OSTEOARTHRITIS OF THE KNEEACTIVE OSTEOARTHRITIS OF THE KNEEEUCTR2006-002590-44-NLWyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development560
进行中（未招募）
不适用
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND COMPARISON OF 4 DOSEREGIMENS OF PLA-695, NAPROXEN, AND PLACEBO ADMINISTERED DAILYFOR 6 WEEKS IN SUBJECTS WITH ACTIVE OSTEOARTHRITIS OF THE KNEEACTIVE OSTEOARTHRITIS OF THE KNEEEUCTR2006-002590-44-HUWyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development560